Tianjin Chase Sun Pharmaceutical

Tianjin Chase Sun Pharmaceutical

Tianjin Chase Sun Pharmaceutical was established in 1996 by Wang Jiang, who retains a roughly 15% individual stake while the state-owned Chengdu Xingcheng Investment Group serves as controlling shareholder. Wenyuan Wu chairs the board, and Wujun Lan runs day-to-day operations as Vice Chairman and General Manager. The firm is headquartered in Tianjin's Wuqing Development Zone and maintains a commercial office in Glen Iris, Victoria, Australia. The firm operates across biomedicine and medical equipment, with an investment posture rooted in traditional Chinese medicine (TCM) herbs and modern pharmaceutical production. Its industrial footprint includes a dedicated pharmaceutical production facility at 17 Yuanquan Road in the Wuqing Development Zone and a technology transfer center on the same campus. The Australian office at 180 Burke Road suggests a focus on cross-border healthcare opportunities, though specific portfolio-company names outside the TCM and production infrastructure remain undisclosed in public filings. The controlling shareholder, Chengdu Xingcheng Investment Group, ties Chase Sun to municipal state capital, giving it access to policy-aligned healthcare initiatives within China. The firm's corporate headquarters sits at Building B01, Entrepreneurship Headquarters Base in Wuqing, placing it inside a designated development zone with likely tax and operational incentives. Team size and aggregate deployment figures are not publicly reported. Chase Sun's structural differentiator is its position as a publicly listed corporate investor majority-controlled by a state entity while retaining a significant founder stake — an architecture that combines state policy tailwinds with entrepreneurial continuity. The Australian office signals an internationalization strategy that remains rare among mid-tier Chinese pharmaceutical corporate investors.